查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1944482

全球药物减敏市场：产业分析、市场规模、份额及按类型、最终用户、销售管道、国家和地区分類的预测（2025-2032 年）

Drug Desensitization Market, By Type, By End-Users, By Sales Channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 328 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024 年药物脱敏市场规模价值 6.021 亿美元，从 2025 年到 2032 年将以 8.07% 的复合年增长率成长。

药物脱敏市场涵盖旨在暂时提高已知存在药物过敏或超敏反应患者对关键药物耐受性的治疗性介入和结构化临床通讯协定，使患者能够在受控的医疗环境中继续接受治疗。药物过敏的日益普遍以及对抗生素、化疗药物和生物製药等第一线治疗药物的依赖性不断增强，是严重市场成长的主要因素。一个关键的市场趋势是转向以先进诊断工具和病患监测技术为支撑的个人化、基于通讯协定的脱敏策略。然而，对训练有素的医疗专业人员的需求、严格的临床监督以及相关的高昂治疗成本是主要的阻碍因素。儘管有这些限制，但临床医生意识的提高以及生物製药和肿瘤疗法的日益普及，为医院和专科医疗机构广泛采用标准化脱敏方案提供了巨大的机会。

药物脱敏的市场动态

药物过敏反应呈上升趋势

药物超敏反应发生率的不断上升是推动全球药物减敏疗法需求成长的主要因素。随着製药业不断扩展至新的治疗领域，越来越多的患者在使用包括抗生素、化疗药物和生物製药在内的基本药物时出现免疫介导的不良反应。这些超敏反应的严重程度差异很大，从轻微的皮疹到危及生命的严重过敏反应，为有效且持续的治疗带来了巨大挑战。根据2023年3月发表的一篇题为「过敏性疾病的发病机制及其对治疗性介入的影响」的综述，药物超敏反应约占所有药物不良反应的5%至10%，影响全球约7%至10%的人口。约8%的个体报告有药物过敏史，但确诊病例则少得多。在儿童族群中，疑似超敏反应占1%至2%，确诊病例约占0.05%。抗生素仍然是最常见的诱发因素，导致约 30% 的严重反应，包括史蒂文斯-约翰逊症候群。

药物减敏市场：細項分析

全球市场已根据类型、最终用户、销售管道和地区进行了市场细分。

按类型划分，舌下免疫疗法（SLIT）凭藉其众多以患者为中心的优势，目前在全球药物脱敏市场中占据领先地位，预计到2025年将占66.1%的市场份额。对患者而言，最显着的益处在于过敏原萃取物或治疗药物透过舌下给药，使患者能够在家中轻鬆舒适地进行治疗，从而避免频繁就医。

2023年10月，美国过敏、气喘和免疫学会（AAAAI）报告称，舌下免疫疗法（SLIT）在三年内使花生过敏儿童的脱敏率达到60%，缓解率达到48%。研究表明，幼儿早期疗育是促进药物减敏和长期过敏缓解的关键因素。

医院和专科过敏诊所是全球药物减敏市场最大的终端用户。这一优势源于它们能够在受控的医疗环境中整合先进的诊断能力、专业的临床知识和多学科患者管理。这些机构凭藉其独特的优势，能够透过个人化的给药通讯协定、持续的病患监测监测以及免疫学家和过敏学家的密切监督，提供安全、精准且循证的药物脱敏治疗。先进脱敏疗法的监管核准也凸显了医院和专科诊所在该领域的重要性。例如，2024年2月，美国食品药物管理局（FDA）核准了由基因泰克和诺华公司联合研发的Zolaia（Omalizumab），这是第一个被证实能够减少意外接触多种食物后过敏反应的药物。这项核准将适应症扩大到 1 岁及以上儿童和患有 IgE 介导的食物过敏的成年人，凸显了医院和专科诊所在提供和管理高级脱敏疗法方面发挥的关键作用。

药物脱敏市场—区域分析

预计到2025年，北美将在全球药物脱敏市场占据关键地位。这得归功于其高度发展的医疗基础设施、许多製药和生物技术公司，以及政府支持过敏管理和免疫耐受疗法创新的政策。此外，该地区还受益于公共和私人研发投入的显着增长，这持续推动着治疗方法的进步和临床应用。例如，2025年9月，总部位于美国的生物製药公司ARS Pharmaceuticals在日本获得了Nefy的监管核准。 Nefy是全球首款也是目前唯一一款用于紧急治疗过敏反应和过敏性休克的无针肾上腺素滴鼻剂。该产品由ARS与Alfresa Holdings Corporation共同开发，将由ARS在日本销售，预计将于2025年第四季开始针对体重15公斤及以上的成人和儿童患者上市。

美国药物脱敏市场—国家分析

美国药物脱敏市场仍然是全球最大的，这得益于其在研发方面的巨额投资、先进的医疗基础设施以及患者中较高的药物和食物过敏患病率。诸如再生元製药（Regeneron Pharmaceuticals）和地平线治疗公司（Horizo​​​​n Therapeutics）等大型製药公司的强大影响力，以及许多成熟的专业过敏治疗中心，正在加速先进脱敏方案在美国的推广通讯协定。例如，2023年9月，雀巢将其花生过敏治疗药物Palforzia出售给了美国公司Stallergenes Glia，该公司在过敏原免疫疗法和药物脱敏领域享有盛誉。 Palforzia是首个核准的口服花生过敏治疗药物，于2020年被雀巢以21亿美元收购，但其商业性应用仍有限。这项收购使 Stallergenes Glia 成为第一家提供呼吸道和食物过敏治疗的公司，使雀巢能够将其策略重点重新集中到胃肠道治疗上。

目录

第一章 药物脱敏市场概览

  • 调查范围
  • 市场预测期

第二章执行摘要

  • 市场区隔
  • 竞争考察

第三章：药物减敏治疗的关键市场趋势

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 未来市场趋势

第四章：药物减敏工作场所调查

  • PEST分析
  • 波特五力分析
  • 成长前景分析
  • 法规结构分析

第五章 药物减敏市场：地缘政治紧张局势加剧的影响

  • 新冠疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章 药物脱敏市场现状

  • 药物脱敏市占率分析（2024 年）
  • 主要製造商的细分数据
    • 对现有公司的分析
    • 新兴企业分析

7. 药物脱敏市场按类型划分

  • 概述
    • 细分市场占有率分析：按类型
    • 皮下免疫疗法（SCIT）
    • 舌下免疫疗法（SLIT）
    • 其他新的免疫疗法递送方法

8. 按最终用户分類的药物脱敏市场

  • 概述
    • 细分市场占有率分析：依最终用户划分
    • 门诊治疗中心
    • 医院和专门的过敏诊所
    • 居家医疗
    • 其他的

9. 按销售管道分類的药物脱敏市场

  • 概述
    • 细分市场占有率分析：依销售管道划分
    • 线上管道
    • 离线频道

10. 各地区药物减敏市场

  • 介绍
  • 北美洲
    • 概述
    • 北美主要製造商
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲主要製造商
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 其他的
  • 亚太地区
    • 概述
    • 亚太地区主要製造商
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 其他的
  • 拉丁美洲
    • 概述
    • 拉丁美洲主要製造商
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 其他的
  • 中东和非洲（MEA）
    • 概述
    • 中东和非洲的主要製造商
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • 其他的

第十一章 主要供应商分析—药物脱敏产业

  • 竞争对手仪錶板
    • 竞争基准
    • 竞争定位
  • 公司简介
    • IDEXX Laboratories Inc
    • ALK-Abello A/S
    • HollisterStier Allergy（Jubilant Pharma）
    • All Cure Pharma Pvt Ltd
    • Allergopharma GmbH and Co KG
    • HAL Allergy Group
    • LETI Pharma
    • Torii Pharmaceutical Co Ltd
    • Inmunotek SL
    • Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
    • DBV Technologies SA
    • Prota Therapeutics Pty Ltd
    • Stallergenes Greer
    • Allergy Therapeutics pIc
    • Aimmune Therapeutics Inc
    • Others

第十二章：分析师视角360度分析

简介目录
Product Code: ANV5995

The Drug Desensitization Market size was valued at US$ 602.10 Million in 2024, expanding at a CAGR of 8.07% from 2025 to 2032.

The drug desensitization market includes therapeutic interventions and structured clinical protocols aimed at temporarily increasing patient tolerance to critical medications in people with known hypersensitivity or allergic reactions, allowing them to continue receiving treatment in controlled healthcare settings. The growing prevalence of drug allergies, as well as the increasing reliance on essential first-line therapies such as antibiotics, chemotherapy agents, and biologics for the treatment of serious and life-threatening conditions, are driving market growth. A significant market trend is the shift toward personalized, protocol-based desensitization strategies that are supported by advanced diagnostic tools and patient monitoring technologies. Nonetheless, the requirement for highly trained medical personnel, intensive clinical oversight, and the associated high treatment costs serve as a major constraint. Despite these limitations, rising clinician awareness and the increasing use of biologics and oncology treatments present significant opportunities for the widespread implementation of standardized desensitization programs in hospitals and specialty care settings.

Drug Desensitization Market- Market Dynamics

Rising Prevalence of Drug Hypersensitivity Reactions

The increasing incidence of drug hypersensitivity reactions is a major factor driving global demand for drug desensitization therapies. As the pharmaceutical industry continues to expand into new therapeutic areas, a growing number of patients are experiencing immune-mediated adverse reactions to essential medications, including antibiotics, chemotherapeutic agents, and biologics. These hypersensitivity reactions vary widely in severity, ranging from mild skin rashes to severe, life-threatening allergic responses, posing significant challenges to effective and continuous treatment. According to a March 2023 review article titled "Pathogenesis of Allergic Diseases and Implications for Therapeutic Interventions," drug hypersensitivity reactions account for approximately 5-10% of all adverse drug reactions and affect nearly 7-10% of the global population. While self-reported drug allergies occur in about 8% of individuals, confirmed cases are considerably lower. In pediatric populations, suspected hypersensitivity reactions affect 1-2%, with confirmed cases around 0.05%. Antibiotics remain the most common triggers, responsible for nearly 30% of severe reactions, including Stevens-Johnson syndrome.

Drug Desensitization Market- Segmentation Analysis:

The worldwide market is segmented on the basis of Type, End-Users, Sales Channel, and Region.

In terms of types, Sublingual Immunotherapy (SLIT), with its numerous patient-centered benefits, is now the market leader in global drug desensitization, accounting for 66.1% by 2025. The most significant factor in the patient-friendly benefits is the administration of allergenic extracts or therapeutic agents under the tongue, which patients perform themselves, providing an easy and comfortable way of treatment at home while avoiding the hassle of frequent clinic visits.

In October 2023, the American Academy of Allergy, Asthma, and Immunology (AAAAI) reported that sublingual immunotherapy (SLIT) resulted in 60% desensitization and 48% remission in peanut-allergic children over three years. According to the research, early childhood intervention is a critical factor in facilitating drug desensitization and long-term allergy remission.

Hospitals and specialized allergy clinics are the largest end-users in the global drug desensitization market. This dominance stems from their ability to combine advanced diagnostic capabilities, specialized clinical expertise, and multidisciplinary patient management in controlled healthcare settings. These facilities are uniquely equipped to perform complex drug desensitization procedures by utilizing individualized dosing protocols, continuous patient monitoring, and close supervision by immunology and allergy specialists, ensuring safe, precise, and evidence-based care. The importance of hospitals and specialty clinics in this segment is emphasized by regulatory approvals of advanced desensitization therapies. For example, in February 2024, the United States Food and Drug Administration approved Xolair (omalizumab), developed by Genentech and Novartis, as the first medication shown to reduce allergic reactions to multiple foods after accidental exposure. This approval, which extends the use to adults and children aged one year and older with IgE-mediated food allergies, emphasizes the critical role of hospital-based and specialty clinics in administering and managing advanced desensitization treatments.

Drug Desensitization Market- Geographical Insights

North America represents a significant region in the global drug desensitization market in 2025, supported by its highly advanced healthcare infrastructure, strong concentration of pharmaceutical and biotechnology companies, and supportive government policies that promote innovation in allergy management and immune tolerance therapies. The region also benefits from substantial public and private investments in research and development, which continue to drive therapeutic advancements and clinical adoption. For example, in September 2025, ARS Pharmaceuticals, a U.S.-based biopharmaceutical company, received regulatory approval in Japan for Neffy, the first and only needle-free epinephrine nasal spray indicated for the emergency treatment of allergic reactions and anaphylaxis. Developed in collaboration with Alfresa Holdings, which will commercialize the product in Japan, Neffy is expected to be available in the fourth quarter of 2025 for adults and pediatric patients weighing more than 15 kilograms.

United States Drug Desensitization Market- Country Insights

The U.S. drug desensitization market remains the largest globally, supported by substantial investments in research and development, advanced healthcare infrastructure, and a high prevalence of drug and food sensitivities among patients. The strong presence of leading pharmaceutical companies such as Regeneron Pharmaceuticals and Horizon Therapeutics, along with well-established specialized allergy treatment centers, is accelerating the adoption of advanced desensitization protocols across the country. For instance, in September 2023, Nestle divested its peanut allergy treatment Palforzia to U.S.-based Stallergenes Greer, a recognized leader in allergen immunotherapy and drug desensitization. Palforzia, the first oral therapy approved by the U.S. FDA for peanut allergy, was originally acquired by Nestle in 2020 for USD 2.1 billion but experienced limited commercial uptake. This acquisition positioned Stallergenes Greer as the first company to offer therapies for both respiratory and food allergies, while enabling Nestle to refocus its strategic priorities on gastrointestinal treatments.

Drug Desensitization Market- Competitive Landscape:

The drug desensitization market is moderately consolidated, with established pharmaceutical companies, specialized allergy therapy providers, and emerging biotech firms specializing in immunology and hypersensitivity management. Market participants compete by developing new products, expanding clinical indications, and forming strategic alliances with hospitals and specialty allergy clinics. Companies are increasing their investment in research and development to improve desensitization protocols, improve patient safety, and broaden applications for food, drug, and biologic allergies. Regulatory approvals and acquisitions remain critical strategies for improving market positioning and expanding product portfolios. Leading players in the market include ALK-Abello A/S, HollisterStier Allergy (Jubilant Pharma), All Cure Pharma Pvt Ltd, and Allergopharma GmbH and Co KG. They use clinical expertise and global distribution networks to maintain a competitive edge and drive market growth.

Recent Developments:

In February 2025, ALK-AbellA/S, a Danish-based global specialty pharmaceutical company specializing in allergy immunotherapy and allergic asthma, has received FDA approval for its DACTRAtablet to treat house dust mite-induced allergic rhinitis in children aged five to eleven. This expands its previous approval for patients aged twelve to sixty-five and strengthens ALK's position in drug desensitization therapy.

In January 2025, Stallergenes Greer, a Swiss biopharmaceutical company that specializes in allergen immunotherapy, has received European Commission approval to extend Palforzia for the treatment of toddlers aged one to three who have a confirmed peanut allergy. Palforzia, the first oral drug desensitization therapy approved by the EMA and the FDA for this age group, promotes tolerance to peanut allergens and reduces the risk of severe allergic reactions.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL DRUG DESENSITIZATION MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • IDEXX Laboratories Inc
  • ALK-Abello A/S
  • HollisterStier Allergy (Jubilant Pharma)
  • All Cure Pharma Pvt Ltd
  • Allergopharma GmbH and Co KG
  • HAL Allergy Group
  • LETI Pharma
  • Torii Pharmaceutical Co Ltd
  • Inmunotek S.L.
  • Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
  • DBV Technologies SA
  • Prota Therapeutics Pty Ltd
  • Stallergenes Greer
  • Allergy Therapeutics pIc
  • Aimmune Therapeutics Inc
  • Others

GLOBAL DRUG DESENSITIZATION MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Subcutaneous Immunotherapy (SCIT)
  • Sublingual Immunotherapy (SLIT)
  • Other emerging immunotherapy delivery methods

GLOBAL DRUG DESENSITIZATION MARKET, BY END-USERS- MARKET ANALYSIS, 2019 - 2032

  • Outpatient treatment centers
  • Hospitals and specialty allergy clinics
  • Homecare settings
  • Others

GLOBAL DRUG DESENSITIZATION MARKET, BY SALES CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Online Channel
  • Offline Channel

GLOBAL DRUG DESENSITIZATION MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Drug Desensitization Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Drug Desensitization Market Snippet by Type
    • 2.1.2. Drug Desensitization Market Snippet by End-Users
    • 2.1.3. Drug Desensitization Market Snippet by Sales Channel
    • 2.1.4. Drug Desensitization Market Snippet by Country
    • 2.1.5. Drug Desensitization Market Snippet by Region
  • 2.2. Competitive Insights

3. Drug Desensitization Key Market Trends

  • 3.1. Drug Desensitization Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Drug Desensitization Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Drug Desensitization Market Opportunities
  • 3.4. Drug Desensitization Market Future Trends

4. Drug Desensitization Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Drug Desensitization Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Drug Desensitization Market Landscape

  • 6.1. Drug Desensitization Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Drug Desensitization Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2024 & 2032 (%)
    • 7.1.2. Subcutaneous Immunotherapy (SCIT)
    • 7.1.3. Sublingual Immunotherapy (SLIT)
    • 7.1.4. Other emerging immunotherapy delivery methods

8. Drug Desensitization Market - By End-Users

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By End-Users, 2024 & 2032 (%)
    • 8.1.2. Outpatient treatment centers
    • 8.1.3. Hospitals and specialty allergy clinics
    • 8.1.4. Homecare settings
    • 8.1.5. Others

9. Drug Desensitization Market - By Sales Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Sales Channel, 2024 & 2032 (%)
    • 9.1.2. Online Channel
    • 9.1.3. Offline Channel

10. Drug Desensitization Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Drug Desensitization Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Drug Desensitization Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.3.8. UK
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. UK Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. UK Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.3.8.5. UK Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.3.9. France
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. France Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.3.9.5. France Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.3.10. Italy
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. Italy Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.3.10.5. Italy Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.3.11. Spain
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.3. Spain Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Spain Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.3.11.5. Spain Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.3.12. The Netherlands
      • 10.3.12.1. Overview
      • 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.3. The Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.12.4. The Netherlands Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.3.12.5. The Netherlands Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Overview
      • 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.3.13.5. Sweden Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.3.14. Russia
      • 10.3.14.1. Overview
      • 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.3. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Russia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.3.14.5. Russia Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Poland Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.3.16. Rest of Europe
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.16.4. Rest of the Europe Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.3.16.5. Rest of the Europe Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Drug Desensitization Key Manufacturers in Asia Pacific
    • 10.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.5. APAC Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 10.4.6. APAC Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.4.7. China
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. China Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.4.7.5. China Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.4.8. India
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. India Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.4.8.5. India Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.4.12. Indonesia
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Indonesia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Indonesia Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.4.13. Thailand
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Thailand Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Thailand Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
  • 10.5. Latin America (LATAM)
    • 10.5.1. Overview
    • 10.5.2. Drug Desensitization Key Manufacturers in Latin America
    • 10.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.5.5. LATAM Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 10.5.6. LATAM Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa (MEA)
    • 10.6.1. Overview
    • 10.6.2. Drug Desensitization Key Manufacturers in Middle East and Africa
    • 10.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.5. MEA Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
    • 10.6.6. MEA Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.6.8. UAE
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. UAE Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. UAE Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.6.8.5. UAE Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Drug Desensitization Industry

  • 11.1. Competitive Benchmarking
    • 11.1.1. Competitive Dashboard
    • 11.1.2. Competitive Positioning
  • 11.2. Company Profiles
    • 11.2.1. IDEXX Laboratories Inc
    • 11.2.2. ALK-Abello A/S
    • 11.2.3. HollisterStier Allergy (Jubilant Pharma)
    • 11.2.4. All Cure Pharma Pvt Ltd
    • 11.2.5. Allergopharma GmbH and Co KG
    • 11.2.6. HAL Allergy Group
    • 11.2.7. LETI Pharma
    • 11.2.8. Torii Pharmaceutical Co Ltd
    • 11.2.9. Inmunotek S.L.
    • 11.2.10. Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
    • 11.2.11. DBV Technologies SA
    • 11.2.12. Prota Therapeutics Pty Ltd
    • 11.2.13. Stallergenes Greer
    • 11.2.14. Allergy Therapeutics pIc
    • 11.2.15. Aimmune Therapeutics Inc
    • 11.2.16. Others

12. 360 Degree AnalystView

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us